Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients

• Published in: Chung-hua fu chʿan kʿo tsa chih Vol. 43; no. 1; p. 5
• Main Authors: Dong, Li, Cui, Heng, Li, Xiao-ping, Sun, Li-fang, Chang, Xiao-hong, Liang, Xu-dong, Zhu, Hong-lan
• Format: Journal Article
• Language: Chinese
• Published: China 01.01.2008
• Subjects: Adult; Antigens, Neoplasm - blood; Biomarkers, Tumor - blood; CA-125 Antigen - blood; CA-19-9 Antigen - blood; Cystadenoma, Mucinous - blood; Cystadenoma, Mucinous - diagnosis; Cystadenoma, Mucinous - surgery; Female; Humans; Middle Aged; Ovarian Neoplasms - blood; Ovarian Neoplasms - diagnosis; Ovarian Neoplasms - surgery; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Survival Analysis
• ISSN: 0529-567X

To evaluate the diagnostic and prognostic value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumors. In this retrospective study, the serum CA19-9, CA125 and CP2 levels of 273 hospitalized patients with ovarian tumors of either mucinous or non-mucinous type were analyzed. (1) CA19-9 had the biggest area under curve (AUC) in mucinous tumors followed with CA125 while CA125 and CP2 had bigger AUC in non-mucinous tumor. (2) For the diagnosis of mucinous tumors, CA19-9 and CA125 combination showed a greatly increased sensitivity compared with CA19-9 or CA125 alone (93.8% versus 75.0% and 66.7%, P<0.05) with no significant improvement of the specificity (P>0.05). For the diagnosis of non-mucinous tumors, CA125 and CP2 combination showed an increased sensitivity compared with CA125 or CP2 alone (85.0% versus 80.7%, P>0.05, 85.0% versus 70.6%, P<0.05) with no significant improvement of the specificity (P>0.05). (3) Seventy percent of tumor marker-positive patients could undergo cytoreductive surgery. Compared w